Literature DB >> 8554382

Prognostic significance in malignant melanoma of nuclear DNA content measured by a microfluorimetric method.

Y Umebayashi1, F Otsuka.   

Abstract

The nuclear DNA content of 47 primary malignant melanomas was measured by 4',6-diamidino-2-phenylindole-DNA (DAPI-DNA) microfluorimetry, and the DNA index, a quantitative measure of nuclear DNA content, was calculated. The DNA index and other clinical and pathological variables were examined and compared with patient survival using univariate and multivariate analyses. The Kaplan-Meier life table method revealed that the DNA index and metastases to regional lymph nodes significantly correlated with patient survival. A Cox proportional hazards multivariate analysis demonstrated that the DNA index, which was not significantly correlated with other variables, was the most reliable and independent factor for predicting patient survival.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8554382     DOI: 10.1007/bf01105795

Source DB:  PubMed          Journal:  Arch Dermatol Res        ISSN: 0340-3696            Impact factor:   3.017


  22 in total

1.  The histogenesis and biologic behavior of primary human malignant melanomas of the skin.

Authors:  W H Clark; L From; E A Bernardino; M C Mihm
Journal:  Cancer Res       Date:  1969-03       Impact factor: 12.701

Review 2.  Flow cytometry in clinical cancer research.

Authors:  B Barlogie; M N Raber; J Schumann; T S Johnson; B Drewinko; D E Swartzendruber; W Göhde; M Andreeff; E J Freireich
Journal:  Cancer Res       Date:  1983-09       Impact factor: 12.701

3.  Epithelioid cell melanomas have greater DNA ploidy abnormalities than spindle cell melanomas: cytological evidence for a higher malignant potential of the former.

Authors:  H I Chi; Y Uyeda; Y Umebayashi; F Otsuka
Journal:  Arch Dermatol Res       Date:  1993       Impact factor: 3.017

4.  Effect of anatomical location on prognosis in patients with clinical stage I melanoma.

Authors:  G S Rogers; A W Kopf; D S Rigel; R J Friedman; J L Levine; M Levenstein; R S Bart; M M Mintzis
Journal:  Arch Dermatol       Date:  1983-08

5.  Flow cytofluorometric DNA analyses of metastases of human malignant melanomas.

Authors:  J Hansson; B Tribukait; R Lewensohn; U Ringborg
Journal:  Anal Quant Cytol       Date:  1982-06

6.  Differential pattern of DNA-aneuploidy in human malignancies.

Authors:  T Büchner; W Hiddemann; B Wörmann; B Kleinemeier; J Schumann; W Göhde; J Ritter; K M Müller; D B von Bassewitz; A Roessner
Journal:  Pathol Res Pract       Date:  1985-01       Impact factor: 3.250

7.  DNA ploidy-characteristics of human malignant melanoma analysed by flow cytometry and compared with histology and clinical course.

Authors:  K Søndergaard; J K Larsen; U Møller; I J Christensen; K Hou-Jensen
Journal:  Virchows Arch B Cell Pathol Incl Mol Pathol       Date:  1983

8.  A prognostic model for clinical stage I melanoma of the upper extremity. The importance of anatomic subsites in predicting recurrent disease.

Authors:  C L Day; A J Sober; A W Kopf; R A Lew; M C Mihm; P Hennessey; F M Golomb; M N Harris; S L Gumport; J W Raker; R A Malt; A B Cosimi; W C Wood; D F Roses; F Gorstein; A Postel; W R Grier; M N Mintzis; T B Fitzpatrick
Journal:  Ann Surg       Date:  1981-04       Impact factor: 12.969

9.  DNA ploidy and S-phase in primary malignant melanoma as prognostic factors for stage III disease.

Authors:  M Karlsson; B Boeryd; J Carstensen; B Kågedal; A T Bratel; S Wingren
Journal:  Br J Cancer       Date:  1993-01       Impact factor: 7.640

10.  DNA aneuploidy and low S-phase fraction as favourable prognostic signs in metastatic melanoma.

Authors:  T Muhonen; S Pyrhönen; A Laasonen; S Asko-Seljavaara; K Franssila
Journal:  Br J Cancer       Date:  1991-10       Impact factor: 7.640

View more
  1 in total

1.  Identification of DAPI-stained normal, inflammatory, and carcinoma hepatic cells based on hyperspectral microscopy.

Authors:  Sifan Lin; Ze Ke; Kunxing Liu; Siqi Zhu; Zhen Li; Hao Yin; Zhenqiang Chen
Journal:  Biomed Opt Express       Date:  2022-03-14       Impact factor: 3.562

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.